HYLAFORM (HYLAN B GEL); PREVELLE SILK

FDA Premarket Approval P030032 S012

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for changes in the methods and specifications for testing the prevelle silk final product (i. E. , 1) changing the average extrusion force specificationfrom less than 80n to an average of average extrusion force specification of less than 40n, 2) changing the maximum peak extrusion force specification of less than 100n to an average of maximum peak extrusion force" specification of less than 50n and 3) changing the method of determining the maximum peak extrusion force specification from the highest single value observed in 10 samples to an average of the maximum peak extrusion force test results observed in 25 samples).

DeviceHYLAFORM (HYLAN B GEL); PREVELLE SILK
Generic NameImplant, Dermal, For Aesthetic Use
ApplicantGENZYME BIOSURGERY
Date Received2011-05-27
Decision Date2011-07-18
PMAP030032
SupplementS012
Product CodeLMH 
Advisory CommitteeGeneral & Plastic Surgery
Supplement TypeReal-time Process
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product Yes
Applicant Address GENZYME BIOSURGERY 55 Cambridge Parkway cambridge, MA 02142

Supplemental Filings

Supplement NumberDateSupplement Type
P030032Original Filing
S017 2014-08-08 30-day Notice
S016 2013-09-25 135 Review Track For 30-day Notice
S015
S014 2011-12-20 135 Review Track For 30-day Notice
S013 2011-09-02 30-day Notice
S012 2011-05-27 Real-time Process
S011
S010 2010-06-09 135 Review Track For 30-day Notice
S009 2009-09-11 30-day Notice
S008 2009-04-15 Normal 180 Day Track No User Fee
S007 2007-07-25 Normal 180 Day Track
S006
S005 2006-01-27 Normal 180 Day Track No User Fee
S004 2005-09-23 Real-time Process
S003 2005-04-20 Normal 180 Day Track No User Fee
S002 2004-07-28 Normal 180 Day Track
S001 2004-06-22 Panel Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.